Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trial Sponsors Should Consider Changing Data Collection Amid COVID-19, US FDA Says

Executive Summary

Quarantines, travel restrictions and supply chain interruptions are likely to cause "unavoidable protocol deviations" in ongoing clinical trials, the FDA says in new guidance that encourages sponsors to consider whether alternative means for conducting safety assessments and collecting efficacy data should be implemented in light of the disruptions caused by COVID-19.

You may also be interested in...



European Commission Recommends Regulatory Midway For COVID-19 Products

The EU is addressing the regulatory obstacles that threaten to reduce the speed at which vital products needed to treat COVID-19 are produced.

COVID-19: US FDA’s Hahn Slams The Brakes On Domestic Inspections ‘For The Health And Well-Being Of Our Staff’

A little more than a month after it put the kibosh on conducting facility inspections in China, the agency announced late on 18 March that it was suspending routine surveillance audits in the US, too.

‘Full-Speed Ahead’: Trump Invokes Korean War Era Law To Fight COVID-19, Shaking Up US Device Manufacturing

Calling himself a “wartime president,” Donald Trump on 18 March invoked the Defense Production Act to push US manufacturers to produce medical products needed to combat COVID-19 – even if those companies aren’t device makers. Trump later signed an Executive Order giving Health and Human Services secretary Alex Azar the power to allocate materials, services and facilities as deemed necessary or appropriate” – all actions covered by the DPA.

Related Content

Topics

UsernamePublicRestriction

Register

MT126426

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel